Aβ40 reduces p-glycoprotein at the blood–brain barrier through the ubiquitin–proteasome pathway

Journal of Neuroscience

Volumn 36, Issue 6, 2016, Pages 1930-1941

  Hartz, Anika M S ^a,b   Zhong, Yu ^a   Wolf, Andrea ^b   LeVine, Harry ^a   Miller, David ^c   Bauer, Björn ^b,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d University of Kentucky   (United States)

Author keywords

Alzheimer s disease; Blood brain barrier; P glycoprotein; Transporter; Ubiquitin proteasome system

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; MULTIDRUG RESISTANCE PROTEIN; PROTEASOME; UBIQUITIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOT HYBRIDIZATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOPRECIPITATION; INTERNALIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UBIQUITINATION; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CAPILLARY; DOSE RESPONSE; DRUG EFFECTS; IN VITRO STUDY; METABOLISM; SPRAGUE DAWLEY RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CAPILLARIES; DOSE-RESPONSE RELATIONSHIP, DRUG; IN VITRO TECHNIQUES; MALE; P-GLYCOPROTEIN; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; UBIQUITIN; UBIQUITINATION;

EID: 84958817297     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0350-15.2016     Document Type: Article

References (44)

1. Aida K, Hayashi H, Inamura K, Mizuno T, Sugiyama Y (2014) Differential roles of ubiquitination in the degradation mechanism of cell surfaceresident bile salt export pump and multidrug resistance-associated protein 2. Mol Pharmacol 85:482–491. CrossRefMedline
2. Akkaya BG, Zolnerciks JK, Ritchie TK, Bauer B, Hartz AMS, Sullivan JA, Linton KJ (2015) The multidrug resistance pump ABCB1 is a substrate for the ubiquitin ligase Nedd4–1. Mol Membr Biol 32:39–45. CrossRefMedline
3. Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS (2006) In vivo activation of human pregnaneXreceptor tightens the blood–brain barrier to methadone through P-glycoprotein upregulation. Mol Pharmacol 70:1212–1219. CrossRefMedline
4. Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, Volta M, Munsie LN, Chou P, Cao LP, Han H, Tapia L, Farrer MJ, Milnerwood AJ (2014) Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci 8:301. CrossRefMedline
5. Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HK, Warzok RW, Vogelgesang S (2011) Beta-amyloid downregulates MDR1-Pglycoprotein (Abcb1) expression at the blood–brain barrier in mice. Int J Alzheimers Dis 2011:690121. CrossRefMedline
6. Carrano A, Snkhchyan H, Kooij G, van der Pol S, van Horssen J, Veerhuis R, Hoozemans J, Rozemuller A, de Vries HE (2014) ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy. Neurobiol Aging 35:565–575. CrossRefMedline
7. Ciechanover A (1994) The ubiquitin–proteasome proteolytic pathway. Cell 79:13–21. CrossRefMedline
8. Ciechanover A, Iwai K (2004) The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life 56:193–201. CrossRefMedline
9. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood–brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285–3290. CrossRefMedline
10. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333–344. CrossRefMedline
11. Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, Richards TL, Mankoff DA, Minoshima S, O’Sullivan F, Eyal S, Hsiao P, Maravilla K, Unadkat JD (2014) Activity of P-glycoprotein, a beta-amyloid transporter at the blood–brain barrier, is compromised in patients with mild Alzheimer disease. J Nucl Med 55:1106-1111. CrossRefMedline
12. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, Suzuki N, Younkin SG (1995) Amyloid beta protein (A beta) in Alzheimer’s disease brain: biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270:7013–7016. CrossRefMedline
13. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356. CrossRefMedline
14. Hartz AM, Bauer B, Fricker G, Miller DS (2004) Rapid regulation of P-glycoprotein at the blood–brain barrier by endothelin-1. Mol Pharmacol 66:387–394. CrossRefMedline
15. Hartz AM, Bauer B, Block ML, Hong JS, Miller DS (2008) Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood–brain barrier. FASEB J 22:2723–2733. CrossRefMedline
16. Hartz AM, Miller DS, Bauer B (2010) Restoring blood–brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. Mol Pharmacol 77:715–723. CrossRefMedline
17. Hong L, Huang HC, Jiang ZF (2014) Relationship between amyloid-beta and the ubiquitin–proteasome system in Alzheimer’s disease. Neurol Res 36:276-282. CrossRefMedline
18. Jeynes B, Provias J (2011) An investigation into the role of P-glycoprotein in Alzheimer’s disease lesion pathogenesis. Neurosci Lett 487:389-393. CrossRefMedline
19. Katayama K, Noguchi K, Sugimoto Y (2013) FBXO15 regulates P-glycoprotein/ ABCB1 expression through the ubiquitin–proteasome pathway in cancer cells. Cancer Sci 104:694-702. CrossRefMedline
20. Keck S, Nitsch R, Grune T, Ullrich O (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. J Neurochem 85:115–122. CrossRefMedline
21. Kim H, Barroso M, Samanta R, Greenberger L, Sztul E (1997) Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. J Physiol 273:C687–C702. Medline
22. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S (2007) MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer’s amyloid-beta peptides: implications for the mechanisms of Abeta clearance at the blood–brain barrier. Brain Pathol 17:347–353. CrossRefMedline
23. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB (2001) beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 76: 1121–1128. CrossRefMedline
24. LeVine H 3rd (2004) Alzheimer’s beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 335:81–90. CrossRefMedline
25. Loo TW, Clarke DM (1998) Quality control by proteases in the endoplasmic reticulum: removal of a protease-sensitive site enhances expression of human P-glycoprotein. J Biol Chem 273:32373–32376. CrossRefMedline
26. Loo TW, Clarke DM (1999) The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem 274:24759-24765. CrossRefMedline
27. Mehta DC, Short JL, Nicolazzo JA (2013) Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer’s disease. Pharm Res 30:2868-2879. CrossRefMedline
28. Mori H, Kondo J, Ihara Y (1987) Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. Science 235:1641–1644. CrossRefMedline
29. Muller C, Laurent G, Ling V (1995) P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol 163:538-544. CrossRefMedline
30. Nuti SL, Rao US (2002) Proteolytic cleavage of the linker region of the human P-glycoprotein modulates its ATPase function. J Biol Chem 277: 29417–29423. CrossRefMedline
31. Oddo S (2008) The ubiquitin–proteasome system in Alzheimer’s disease. J Cell Mol Med 12:363–373. CrossRefMedline
32. O’Neill RA, Bhamidipati A, Bi X, Deb-Basu D, Cahill L, Ferrante J, Gentalen E, Glazer M, Gossett J, Hacker K, Kirby C, Knittle J, Loder R, Mastroieni C, Maclaren M, Mills T, Nguyen U, Parker N, Rice A, Roach D, et al. (2006) Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci U S A 103:16153–16158. CrossRefMedline
33. Park R, Kook SY, Park JC, Mook-Jung I (2014) Abeta1–42 reduces P-glycoprotein in the blood–brain barrier through RAGE-NF-kappaB signaling. Cell Death Dis 5:e1299. CrossRefMedline
34. Perry G, Friedman R, Shaw G, Chau V (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A 84:3033–3036. CrossRefMedline
35. Schramm U, Fricker G, Wenger R, Miller DS (1995) P-glycoproteinmediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. J Physiol 268:F46-F52. Medline
36. Stine WB, Jungbauer L, Yu C, LaDu MJ (2011) Preparing synthetic Abeta in different aggregation states. Methods Mol Biol 670:13–32. CrossRefMedline
37. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Müller M, Scheltens P, Lammertsma AA, van Berckel BN (2012) Blood–brain barrier P-glycoprotein function in Alzheimer’s disease. Brain 135:181–189. CrossRefMedline
38. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW (2002) Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12: 535–541. CrossRefMedline
39. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, Siegmund W, Walker LC, Pahnke J (2004) The role of P-glycoprotein in cerebral amyloid angiopathy: implications for the early pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 1:121–125. CrossRefMedline
40. Wijesuriya HC, Bullock JY, Faull RL, Hladky SB, Barrand MA (2010) ABC efflux transporters in brain vasculature of Alzheimer’s subjects. Brain Res 1358:228-238. CrossRefMedline
41. Yi JJ, Ehlers MD (2007) Emerging roles for ubiquitin and protein degradation in neuronal function. Pharmacol Rev 59:14-39. CrossRefMedline
42. Zhang Z, Wu JY, Hait WN, Yang JM (2004) Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 66:395–403. CrossRefMedline
43. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 28:202–208. CrossRefMedline
44. Zlokovic BV, Frangione B (2003) Transport-clearance hypothesis for Alzheimer’s disease and potential therapeutic implications in Abeta metabolism in Alzheimer’s disease. Austin, TX: Landes Bioscience.